Three things to know:
1. The robot has been approved for laparoscopy for general surgery, gynecology, urology and specific thoracic procedures.
2. Senhance’s goal is to improve the precision, senses and control of surgeons in minimally invasive laparoscopic procedures.
3. “Japan is second only to the U.S. as the world’s largest surgical robotics market” and “creates a considerable market opportunity for Senhance,” said Todd M. Pope, president and CEO of TransEnterix.
More articles on devices:
Exactech acquires EPIC Extremity, expands foot and ankle portfolio — 4 insights
Surgeon co-founded device company launches orthopedic drill
10 major updates from NuVasive in the last 6 months
